Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Extension Study of rhASB in Mucopolysaccharidosis VI
NCT00104234Phase 3Completed
- Sponsor
- BioMarin Pharmaceutical
- Start
- Feb 2004
- Primary completion
- Oct 2006
- Modality
- Replacement Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label trial of galsulfase in mucopolysaccharidosis type VI (2 arms), sponsored by BioMarin Pharmaceutical. Primary endpoint: 12-Minute Walk Test at 96 weeks. Started Feb 2004; status: completed.
02
Drugs
galsulfase
03
Conditions
mucopolysaccharidosis type VI
Beyond the preview
Go deeper on NCT00104234.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00104234.